Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.

The CHMP recommended approval of the subcutaneous formulation of RoActemra for use both as monotherapy and in combination with methotrexate.

The positive opinion from the CHMP was based on encouraging data from two phase III studies – SUMMACTA and BREVACTA.

The data from the SUMMACTA study showed that the efficacy and tolerability of subcutaneous RoActemra was comparable with the intravenous (IV) formulation of RoActemra.

We remind investors that RoActemra is approved in the EU for the treatment of moderate-to-severe RA who did not respond adequately or were intolerant to, previous medication with one or more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) inhibitors.

RoActemra IV formulation is also approved for the treatment of active systemic juvenile idiopathic arthritis (SJIA) and polyarticular juvenile idiopathic arthritis (PJIA) in patients aging two years and above.

We note that RoActemra is marketed as Actemra in the U.S. The subcutaneous formulation of the drug was approved in the U.S. in Oct 2013. 

Roche has launched the subcutaneous injection formulation of Actemra in Japan in May 2013.

Sales of Actemra grew 33% in the first nine months of 2013. The subcutaneous formulation should boost sales of Actmera going forward benefiting from its increased use as a monotherapy in RA.

However, competition is stiff in the RA market given the presence of treatments like UCB’s (UCBJF) Cimzia and AbbVie Inc.’s (ABBV - Analyst Report) Humira, among others.

Roche currently carries a Zack Rank #3 (Hold). Right now, Shire (SHPG - Analyst Report) appears to be well placed with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%